Luc-André Granier MD, PhD
Chief Executive Officer, Medical Director & Co-Founder
Luc-André Granier co-founded Advicenne in 2007 and is the company’s CEO, Medical Director and Chairman of the Board. He is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system, and brings to Advicenne more than twenty-five years of experience in the pharmaceutical and biotech industries.
In his work with companies such as Eli Lilly and Company, Synt:em and Forenap, Luc-André has overseen a number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, primarily in the areas of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.
Luc-André holds Doctor of Medicine and Doctor of Science degrees from Louis Pasteur University (Strasbourg, France), where he specialized in biochemistry, and molecular and cellular biology. He is a member of several national and international scientific societies in the fields of pain, epilepsy and renal diseases, including the International League Against Epilepsy (ILAE), American Society of Nephrology (ASN) and the International Pediatric Nephrology Association (IPNA).
Director of Operations, General Manager & Co-Founder
Caroline Roussel-Maupetit co-founded Advicenne and has served as the company’s Director of Operations since its inception in 2007, and as its General Manager since 2011.
Having participated in the creation of three French biotechnology companies, Caroline brings to her work at Advicenne an extensive background in the pharmaceutical development of innovative therapeutic products, in particular in its technical and regulatory aspects, and in the area of subcontracting management.
In 1995, Caroline co-founded Syn:tem, a French biotech company focused on the treatment of oncology, pain management and diseases of the central nervous system, serving as the company’s Chief Operating Officer until its acquisition by CLL Pharma SA in 2005. Prior to founding Synt:em, she served as Marketing Manager for Protein Performance, a company specializing in the development of recombinant proteins.
Caroline holds degrees in industrial biological engineering from the University of Technology of Compiègne (UTC) and in management from IEDE Montpellier.
Ludovic Robin PharmD
Chief Business Officer
Ludovic Robin joined Advicenne in August 2016 in the role of Chief Business Officer and is responsible for marketing of drugs under development in key regions such as the United States and Europe.
Over the last twenty-five years, Ludovic has held numerous managerial positions in France and abroad, providing leadership in the pharmaceutical industry in the areas of international research and development, business development, as well as marketing and sales. In particular, he has participated in the launch of more than fifteen original products for rare diseases and patient care.
Ludovic began his career as a scientist in the United Kingdom, where he developed new cosmetic and dermatological formulations for Procter & Gamble and Stiefel Laboratories. Subsequently he held various managerial and leadership roles in sales, marketing and business development at L’Oréal, Servier and Laboratoires Expanscience. During this period he originated, signed and executed thirteen commercial partnerships in more than twenty countries.
In 2004, Ludovic joined Shire for the launch of its dermatology and nephrology franchises. During his twelve years with the company, he went on to serve as Marketing Manager, Business Unit Director, Marketing Director and Commercial Operations Head of France/Benelux, focusing on nephrology and child psychiatry. While at Shire he was a member of the French Executive Board from 2008 to 2016.
Ludovic holds a Doctor of Pharmacy (PharmD) from Lyon I University, a Master’s in Industrial Pharmacy from Lyon Institute of Industrial Pharmacy (Institut de Pharmacie Industrielle de Lyon (Lyon I University)), and an MBA from HEC Paris (with McGill University (Montréal, Canada)).
Chief Financial Officer
Paul Michalet is Advicenne’s Chief Financial Officer, a position to which he brings nearly thirty years of experience in executive management. After a decade serving in management positions in the manufacturing and service sectors, Paul has spent the last twenty years in senior executive roles with biotechnology companies active in the chemical, cosmetics and pharmaceutical industries.
Prior to joining Advicenne, Paul was Chief Executive Officer of iDD biotech, a biotechnology company specializing in monoclonal antibody drug development in the oncology field. He also served as CFO and Chief Business Officer in charge of strategy, financing and business development for Fermentalg, an industrial biotech company listed on Compartment C of Eurolist Paris, for which he negotiated the joint venture with Sofiprotéol.
In his various senior positions, Paul has negotiated several important license agreements and raised over two hundred million Euros through various transactions, including three successful IPOs: Fermentalg (2014), MetabolicExplorer (2007) and Coletica, now BASF Beauty Care Solutions (2000), for which he also prepared the trade sale.
A graduate of Montpellier Business School, Paul is a member of the French Society of Financial Analysts (SFAF) and the French Institute of Board Directors (IFA).
Catherine Guittet PharmD
Head of Clinical Operations Department
Catherine Guittet joined Advicenne in 2008 and is responsible for clinical research, regulatory affairs and project management. With over fifteen years of experience in clinical affairs and regulatory matters, Catherine has held positions with Merck Serono, where she managed a unit dedicated to the coordination of early clinical development in oncology, as well as with the French biotech company, Synt:em. For several years, she served as Head of the Patient Clinical Study Unit at SGS-Aster (a contract research organization). Catherine began her career as Head of Project Management at Theraplix (Sanofi-Aventis).
Catherine received her Doctor of Pharmacy (PharmD) and PhD from Angers University, graduated as Clinical Investigator from Paris VII University, obtained a Pharmaco-Epidemiology Certificate from Bordeaux II University, as well as a Cellular Pharmacology, Pharmacogenetics and Pharmacokinetics Certificate from Paris VII University.
Nathalie Lemarié PharmD
Director of Regulatory Affairs & Qualified Person
Nathalie Lemarié joined the Advicenne management team in October 2012 and oversees product registration as well as regulatory matters. She has over two decades of experience in regulatory affairs, both in France and abroad, which she acquired at Laboratoire Chauvin (France), where she was Regulatory Affairs Manager, coordinating the group’s European subsidiaries and putting in place European registration procedures.
Nathalie obtained her Doctor of Pharmacy (PharmD) and Masters in Business Administration at the University of Montpellier.
Financial & Logistics Director
Sarah Delbaere joined Advicenne in November 2013 as Financial and Logistics Director. She has more than fifteen years of experience in the pharmaceutical and biotech sectors, having served as Finance and Administrative Director at Takeda Pharmaceuticals and at Nycomed, where she was responsible for finance, supply chain, legal and general administration, and was involved in the merger and strategic reorganization of the company. Previously, Sarah held positions at Gencell, an affiliate of Sanofi-Aventis specializing in gene therapy, and at Innogenetics, a Belgian biotech company listed on the NASDAQ.
Sarah is a graduate in Applied Economics from the University of Antwerp in Belgium.
Julie Rachline PhD
Julie Rachline joined Advicenne in November 2015 to support corporate development and investor relations.
As a private equity investor, Julie invested in diverse companies such as BrainEver, HalioDx, Nanobiotix (Ticker: NANO) and Eurogentec (sold to Kaneka), serving on the boards of these companies as well as those of Voluntis and Stimulus. As a former Principal at L3S partnership, where she was involved in or led recruitments for pharma, medtech, ANSM and the French Biomedicine Agency (Agence de la Biomédecine), Julie also brings to her work at Advicenne a strong background in executive search.
Julie holds a PhD in Neuropharmacology from Ecole Normale Supérieure and an MS from ESCP Europe.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne